| Code | CSB-RA011593MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CALY-002, targeting interleukin-15 (IL-15), a pleiotropic cytokine that plays critical roles in immune cell homeostasis and function. IL-15 promotes the development, proliferation, and survival of natural killer cells, CD8+ T cells, and memory T lymphocytes through signaling via the IL-15 receptor complex. This cytokine is implicated in various immune-mediated conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where elevated IL-15 levels contribute to chronic inflammation and tissue damage. Additionally, IL-15 has been associated with certain T-cell malignancies and plays a role in transplant rejection and autoimmune disorders.
CALY-002 is a therapeutic antibody candidate developed for treating immune-mediated inflammatory diseases by neutralizing IL-15 activity. This biosimilar antibody serves as a valuable research tool for investigating IL-15 biology, exploring cytokine-mediated immune responses, and studying potential therapeutic interventions in autoimmune and inflammatory disease models. It enables researchers to evaluate IL-15 blockade strategies and understand the cytokine's contribution to various pathological conditions.
There are currently no reviews for this product.